ERBB2 and ductal breast carcinoma in situ: Interestingly it was observed that a significant percentage of this high risk population was HER2 positive, further validating the findings from previous studies that DCIS shares similar genomic heterogeneity to invasive breast cancer comprising lesions that vary in their clinical presentation and outcomes.